Revlimid
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Revlimid |
|---|---|
| Active Substance | lenalidomid |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| ATC Code | L04AX04 |
| Medicinal product marketed in the Croatia | Trajni prekid opskrbe |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
| Educational materials for healthcare professionals |
Vodič za zdravstvene radnike, verzija 4 Obrazac pristanka bolesnika, verzija 3 Obrazac prijave trudnoće, verzija 3 |
| Educational materials for patients / caregivers |
Vodic za bolesnike, verzija 4 Kartica za bolesnika, verzija 3 |
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o novim važnim preporukama s obzirom na reaktivaciju virusa uz primjenu lenalidomida (Revlimid) | 08.11.2016 | Celgene Europe Limited |
